BNGO Stock Overview
Provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Bionano Genomics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.20 |
| 52 Week High | US$2.27 |
| 52 Week Low | US$0.20 |
| Beta | 2.26 |
| 1 Month Change | -6.88% |
| 3 Month Change | -51.91% |
| 1 Year Change | -88.46% |
| 3 Year Change | -99.40% |
| 5 Year Change | -98.19% |
| Change since IPO | -99.72% |
Recent News & Updates
Recent updates
Bionano Genomics, Inc. (NASDAQ:BNGO) Might Not Be As Mispriced As It Looks
Dec 17
Many Still Looking Away From Bionano Genomics, Inc. (NASDAQ:BNGO)
Aug 29Market Cool On Bionano Genomics, Inc.'s (NASDAQ:BNGO) Earnings Pushing Shares 31% Lower
May 09Bionano Genomics, Inc. (NASDAQ:BNGO) Analysts Just Trimmed Their Revenue Forecasts By 9.0%
Mar 14Shareholder Returns
| BNGO | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | -18.7% | -2.1% | -2.4% |
| 1Y | -88.5% | -5.5% | 23.3% |
Return vs Industry: BNGO underperformed the US Life Sciences industry which returned -5.5% over the past year.
Return vs Market: BNGO underperformed the US Market which returned 23.3% over the past year.
Price Volatility
| BNGO volatility | |
|---|---|
| BNGO Average Weekly Movement | 11.4% |
| Life Sciences Industry Average Movement | 9.2% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: BNGO's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: BNGO's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 344 | Robert Holmlin | www.bionano.com |
Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA. The company also provides Saphyr and Bionano compute servers; and VIA software, which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics.
Bionano Genomics, Inc. Fundamentals Summary
| BNGO fundamental statistics | |
|---|---|
| Market cap | US$20.45m |
| Earnings (TTM) | -US$135.78m |
| Revenue (TTM) | US$33.33m |
0.6x
P/S Ratio-0.1x
P/E RatioIs BNGO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BNGO income statement (TTM) | |
|---|---|
| Revenue | US$33.33m |
| Cost of Revenue | US$33.93m |
| Gross Profit | -US$599.00k |
| Other Expenses | US$135.18m |
| Earnings | -US$135.78m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.33 |
| Gross Margin | -1.80% |
| Net Profit Margin | -407.34% |
| Debt/Equity Ratio | 30.6% |
How did BNGO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 22:42 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Bionano Genomics, Inc. is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mark Massaro | BTIG |
| Constantine Davides | D. Boral Capital LLC. |
| Jeffrey Cohen | Ladenburg Thalmann & Company |